{
    "nct_id": "NCT06325748",
    "official_title": "SENTI-202-101: a Phase 1, Multicenter, Open-Label Study of SENTI-202, a Selective Off-the-Shelf Logic Gated CAR NK Cell Therapy, in Subjects with CD33 And/or FLT3 Expressing Malignancies",
    "inclusion_criteria": "* Subjects with CD33 and/or FLT3 expressing malignancies, including:\n\n  * Relapsed refractory acute myeloid leukemia (AML) with morphologic relapse as defined by ≥5% bone marrow blasts who have received at least 1 prior line, but no more than 3 prior lines of standard anti-AML therapy. Subjects with FLT3-mutated or IDH ½-mutated disease must have received at least one prior targeted therapy.\n  * Relapsed refractory myelodysplastic syndrome (MDS) with increased blasts who have received at least 1 prior line, but no more than 2 prior lines of anti-MDS therapy\n  * Other hematological malignancies who have received at least 1 prior line of standard of care for the respective disease\n  * Documentation of CD33 expression (or FLT3 expression if available) by individual institutional standard of care\n* ECOG performance score of 0-1\n* Adequate organ function including platelet count >20x109/L (platelet transfusion is permitted)\n* Adequate recovery from toxicities from previous cancer treatments, as described in the study protocol\n* Willing and able to provide written informed consent\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 74 Years",
    "exclusion_criteria": "* White blood cell (WBC) count of ≥20×109/L or circulating blasts ≥10×109/L or rapidly progressive/hyperproliferative disease\n* Acute promyelocytic leukemia with t(15;17) (q22;q12) or abnormal promyelocytic leukemia/retinoic acid receptor alpha (APML-RARA)\n* MDS with fibrosis (MDS-f) or known prior history of constitutional conditions/syndromes with chemo-responsive AML\n* Evidence of leukemic meningitis or known active central nervous system disease\n* Presence of extra-medullary disease or myeloid sarcoma alone with no morphologic hematologic relapse\n* Prior use of certain anti-cancer therapies and/or use within a certain number of days prior to SENTI-202 study treatment, as described in the study protocol\n* Hematopoietic cell transplantation (HCT) less than 100 days prior to the first dose of SENTI-202\n* Prior NK cell or CAR T cell therapy at any time\n* Prior donor lymphocyte infusion (DLI), except if after HCT for MRD+ disease\n* Medical conditions or medications prohibited by the study protocol\n* Pregnant or breastfeeding female",
    "miscellaneous_criteria": ""
}